Abstract: A vehicle structure can include a coating that provides a three-dimensional tactile pattern to the vehicle structure. In addition, a method for forming a vehicle structure can include applying a film that provides a three-dimensional tactile pattern to the vehicle structure. The vehicle structure can be a trim piece of a vehicle to which the film provides decorative and tactile features. A thin metal layer can be applied on top of a substrate by a metallizing technique, such as physical vapor deposition, followed by applying a radiation curable formulation and exposing it to radiation source, such as UV light. The radiation curable formulation can be a UV ink that is spaced at separate and distinct locations on the film and extends from the metallic layer to such an extent that it is discernable by human touch.

Abstract: A vehicle structure can include a coating that provides a three-dimensional tactile pattern to the vehicle structure. In addition, a method for forming a vehicle structure can include applying a film that provides a three-dimensional tactile pattern to the vehicle structure. The vehicle structure can be a trim piece of a vehicle to which the film provides decorative and tactile features. A thin metal layer can be applied on top of a substrate by a metallizing technique, such as physical vapor deposition, followed by applying a radiation curable formulation and exposing it to radiation source, such as UV light. The radiation curable formulation can be a UV ink that is spaced at separate and distinct locations on the film and extends from the metallic layer to such an extent that it is discernable by human touch.

Abstract: The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.

Abstract: The present invention provides machine readable storage media comprising a three-dimensional representation of Interleukin-1 Hy2 (IL-1Hy2), useful for designing and producing modulators of its activity and IL-1 Hy2 variants, and therapeutic uses thereof. The present invention also provides novel nucleic acids encoding IL-1 Hy2, the novel polypeptides encoded by these nucleic acids and uses of these and related products.

Abstract: The present invention provides nucleic acids, the polypeptide sequences encoded by these nucleic acids and uses thereof. These polynucleotide and polypeptide sequences were determined to be a Interleukin-1 Receptor Antagonist. Assays for detection of the Interleukin-1 Receptor Antagonist and assays in which the antagonist is used for detection of IL-1 Receptor are also described.

Abstract: The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.

Abstract: The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist. Also provided are antibodies which bind the antagonist, methods of detecting the antagonist, and kits containing the antibodies.